Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

Abstract: Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract Compositions containing an Uncaria tomentosa extract in combination with an oolong tea extract.

Abstract: Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract. Compositions containing an Uncaria tomentosa extract in combination with an oolong tea extract.

Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

Abstract: Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract Compositions containing an Uncaria tomentosa extract in combination with an oolong tea extract.

Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of ?-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Abstract: The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Methods and devices for data entry are disclosed. An example method includes executing an application on a mobile device, the application requiring a login to access at least a portion of data accessible via the application, accessing a store of email addresses associated with a user of the mobile device, the email addresses including at least a forwarding email address, and presenting the email addresses including the forwarding email address for selection as the login.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

Abstract: A method and handheld electronic device for triggering the display of content on a display screen are provided. In accordance with one embodiment, there is provided a method of triggering the display of content on a display screen of a handheld electronic device, the method comprising: monitoring for the occurrence of trigger conditions comprising one or more of: inputs to change an operational mode of the handheld electronic device, changes in orientation of the handheld electronic device, or changes in a screen orientation of a graphical user interface (GUI) displayed on the display screen; and reproducing content on the handheld electronic device in response to detection of one of the trigger conditions.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of ?-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of ?-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.

Abstract: A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where: R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and an

Abstract: Methods and devices for data entry are disclosed. An example method includes executing an application on a mobile device, the application requiring a login to access at least a portion of data accessible via the application, accessing a store of email addresses associated with a user of the mobile device, the email addresses including at least a forwarding email address, and presenting the email addresses including the forwarding email address for selection as the login.

Abstract: Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.